


CP-461 free base

Chemical Properties

CAS No. :	227619-92-3
Formula:	C ₂₅ H ₂₁ FN ₂ O
Molecular Weight:	384.45
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	CP-461 (OSI-461) is a pde2a / 5A inhibitor, which may be used in the treatment of renal cell carcinoma, prostate cancer, and Crohn's disease.
Targets(IC50)	Apoptosis,Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6011 mL	13.0056 mL	26.0112 mL
5 mM	0.5202 mL	2.6011 mL	5.2022 mL
10 mM	0.2601 mL	1.3006 mL	2.6011 mL
50 mM	0.052 mL	0.2601 mL	0.5202 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Singh R, Fröbel J, Cadeddu RP, Bruns I, Schroeder T, Brännert D, Wilk CM, Zerbini LF, Haas R, Czibere A. The novel compound OSI-461 induces apoptosis and growth arrest in human acute myeloid leukemia cells. *Ann Hematol.* 2012 Feb;91(2):173-81. doi: 10.1007/s00277-011-1282-4. PubMed PMID: 21717102.

Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. *Cancer Chemother Pharmacol.* 2011 Feb;67(2):431-8. doi: 10.1007/s00280-010-1328-7. PubMed PMID: 20445979; PubMed Central PMCID: PMC3028086.

O'Bryant CL, Lieu CH, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. *Cancer Chemother Pharmacol.* 2009 Feb;63(3):477-89. doi: 10.1007/s00280-008-0761-3. PubMed PMID: 18509645; PubMed Central PMCID: PMC2814254.

Xiao D, Deguchi A, Gundersen GG, Oehlen B, Arnold L, Weinstein IB. The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization. *Mol Cancer Ther.* 2006 Jan;5(1):60-7. PubMed PMID: 16432163.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481